News
VNRX
0.6979
-2.61%
-0.0187
Weekly Report: what happened at VNRX last week (0826-0830)?
Weekly Report · 5d ago
VolitionRX Price Target Announced at $5.00/Share by EF Hutton
Dow Jones · 08/26 15:17
VolitionRX Coverage Assumed by EF Hutton at Buy
Dow Jones · 08/26 15:17
EF Hutton Assumes VolitionRX at Buy, Announces Price Target of $5
Benzinga · 08/26 15:08
Weekly Report: what happened at VNRX last week (0819-0823)?
Weekly Report · 08/26 12:03
Weekly Report: what happened at VNRX last week (0812-0816)?
Weekly Report · 08/19 11:46
Volitionrx: Statement of changes in beneficial ownership of securities
Press release · 08/16 22:07
Benchmark Reiterates Hold on VolitionRX
Benzinga · 08/16 13:50
Benchmark Co. Remains a Hold on VolitionRX (VNRX)
TipRanks · 08/16 11:36
VolitionRX reports Q2 results
Seeking Alpha · 08/15 08:04
VOLITIONRX LIMITED QUARTERLY REPORT ON FORM 10-Q FOR THE SIX MONTHS ENDED JUNE 30, 2024
Press release · 08/15 01:17
VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024
Investorplace · 08/15 00:53
Here's the major earnings before the open tomorrow
Seeking Alpha · 08/14 22:00
VolitionRX Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $395.80K Miss $480.00K Estimate
Benzinga · 08/14 20:22
Volitionrx: Prospectus [Rule 424(b)(5)]
Press release · 08/12 14:11
Weekly Report: what happened at VNRX last week (0805-0809)?
Weekly Report · 08/12 11:49
VolitionRx prices its $21.5M direct offering
Seeking Alpha · 08/09 12:26
VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
PR Newswire · 08/06 12:00
Weekly Report: what happened at VNRX last week (0729-0802)?
Weekly Report · 08/05 12:03
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.